Patents by Inventor Robert Langland EIL

Robert Langland EIL has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12365871
    Abstract: The preset disclosure provides methods of culturing cells, e.g., pluripotent cells, multipotent cells, and/or immune cells (e.g., T cells, NK cells, and/or TILs) in a medium comprising at least about 5 mM potassium ion, wherein the medium is not hypertonic. In some aspects, the medium is hypotonic. In some aspects, the methods disclosed herein increases the number of less-differentiated cells in the population of cells. In some aspects, the cultured cells are engineered, e.g., to comprise a chimeric antigen receptor or an engineered T cell receptor. In some aspects, the cells are administered to a subject in need thereof.
    Type: Grant
    Filed: April 28, 2021
    Date of Patent: July 22, 2025
    Inventors: Suman Kumar Vodnala, Nicholas P. Restifo, Robert Langland Eil
  • Publication number: 20240228957
    Abstract: The preset disclosure provides methods of culturing cells, e.g., pluripotent cells, multipotent cells, and/or immune cells (e.g., T cells and/or NK cells) in a medium comprising at least about 5 mM potassium ion, wherein the medium is not hypertonic. In some aspects, the medium is hypotonic. In some aspects, the methods disclosed herein increases the number of less-differentiated cells in the population of cells. In some aspects, the cultured cells are engineered, e.g., to comprise a chimeric antigen receptor or an engineered T cell receptor. In some aspects, the cells are administered to a subject in need thereof.
    Type: Application
    Filed: February 24, 2022
    Publication date: July 11, 2024
    Applicant: Lyell Immunopharma, Inc.
    Inventors: Suman Kumar VODNALA, Yogin PATEL, Nicholas P. RESTIFO, Robert Langland EIL
  • Publication number: 20240132840
    Abstract: The preset disclosure provides methods of culturing cells, e.g., pluripotent cells, multipotent cells, and/or immune cells (e.g., T cells and/or NK cells) in a medium comprising at least about 5 mM potassium ion, wherein the medium is not hypertonic. In some aspects, the medium is hypotonic. In some aspects, the methods disclosed herein increases the number of less-differentiated cells in the population of cells. In some aspects, the cultured cells are engineered, e.g., to comprise a chimeric antigen receptor or an engineered T cell receptor. In some aspects, the cells are administered to a subject in need thereof.
    Type: Application
    Filed: February 24, 2022
    Publication date: April 25, 2024
    Applicant: Lyell Immunopharma, Inc.
    Inventors: Suman Kumar VODNALA, Yogin PATEL, Nicholas P. RESTIFO, Robert Langland EIL
  • Publication number: 20210332326
    Abstract: The preset disclosure provides methods of culturing cells, e.g., pluripotent cells, multipotent cells, and/or immune cells (e.g., T cells, NK cells, and/or TILs) in a medium comprising at least about 5 mM potassium ion, wherein the medium is not hypertonic. In some aspects, the medium is hypotonic. In some aspects, the methods disclosed herein increases the number of less-differentiated cells in the population of cells. In some aspects, the cultured cells are engineered, e.g., to comprise a chimeric antigen receptor or an engineered T cell receptor. In some aspects, the cells are administered to a subject in need thereof.
    Type: Application
    Filed: April 28, 2021
    Publication date: October 28, 2021
    Applicant: LYELL IMMUNOPHARMA, INC.
    Inventors: Suman Kumar VODNALA, Nicholas P. RESTIFO, Robert Langland EIL